Thanks for keeping us up to date! That article says that: Type 2 diabetes is the leading cause of CKD and there have been no new medicines to treat or prevent CKD in more than 17 years.
Once that new indication for Invokana gets through, it is expected to put J & J ahead of its rivals. Do you know anything about priority review by the FDA? It would be good if we could monitor that.
Ann: Appendix 4C - March 2019 Quarterly Report, page-31
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.015(4.92%) |
Mkt cap ! $47.42M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 28.5¢ | $191.2K | 643.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53694 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 51000 | 2 |
View Market Depth
| Last trade - 15.36pm 26/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |